Background and aims Anthracyclines can cause cancer therapy-related cardiac dysfunction
(CTRCD). We aimed to assess whether statins prevent decline in left ventricular ejection …

Simple Summary Cancer therapy-related cardiac dysfunction (CTRCD) has been an urgent
medical issue in patients that receive breast cancer therapies including anthracycline-based …

Cancer is one of the most widespread diseases globally and one of the leading causes of
death. Known cancer treatments are chemotherapy, surgery, radiation therapy, targeted …

Breast cancer chemotherapy/immunotherapy can be associated with treatment-limiting
cardiotoxicity. Radiomics techniques applied to ultrasound, known as ultrasomics, can be …

A growing body of evidence on a wide spectrum of adverse cardiac events following
oncologic therapies has led to the emergence of cardio-oncology as an increasingly …

Background Cardiac magnetic resonance imaging (CMR) is the gold standard for measuring
infarct size (IS). However, this method is expensive and requires a specially trained …

The emerging use of immunotherapies in cancer treatment increases the risk of
immunotherapy-related cardiotoxicity. In contrast to conventional chemotherapy, these novel …

Abstract Purpose of Review Cancer patients are at risk for treatment-related myocardial
dysfunction and heart failure during or after treatment. Risk prediction models have the …

Background Pediatric acute myeloid leukemia (AML) therapy is associated with substantial
short-and long-term treatment-related cardiotoxicity mainly due to high-dose anthracycline …

Background Cardiac magnetic resonance (CMR) has been used to diagnose and risk-
stratify patients with left ventricular noncompaction (LVNC). The prognostic value of CMR …